Shin, Dong-Joo http://orcid.org/0009-0007-7522-7903
Choi, Young Hun http://orcid.org/0000-0002-1842-9062
Lee, Seul Bi http://orcid.org/0000-0002-5163-3911
Cho, Yeon Jin http://orcid.org/0000-0001-9820-3030
Lee, Seunghyun http://orcid.org/0000-0003-1858-0640
Cheon, Jung-Eun http://orcid.org/0000-0003-1479-2064
Funding for this research was provided by:
TAEJOON Pharmaceutical
Seoul National University
Article History
Received: 21 December 2023
Revised: 12 May 2024
Accepted: 13 May 2024
First Online: 5 June 2024
Change Date: 4 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00247-024-05996-4
Declarations
:
: Our Institutional Review Board approved this retrospective study and waived the requirement for informed consent.
: A condition of the funders of this project (Taejoon Pharmaceutical Co., Seoul, South Korea) was that the research team should use the company’s own contrast agent (Iobrix 240) in the conduct of the study.